Navigation Links
Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
Date:10/10/2008

EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold a conference call on Monday, October 13, to provide an update on the Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke. Hosting the call will be Paul E. Freiman, president and chief executive officer and Warren W. Wasiewski, chief medical officer.

-- Date: Monday, October 13, 2008

-- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT)

-- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942

International

Telephonic Replay: A playback of the conference call will be available

from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20,

2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International

Pass code: 9164451

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
2. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
3. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies CEO to Retire on December 31, 2008
5. Neurobiological Technologies Reports Third Quarter Financial Results
6. Neurobiological Technologies Sets Date for Third Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
8. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
9. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
10. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
11. Neurobiological Technologies Sets Date for Research and Development Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... Yorba Linda, Ca (PRWEB) , ... ... ... stem cells (PSCs) offer an unlimited source of human cardiovascular cells for ... efficient cardiac-directed differentiation methods makes it possible to generate large numbers of ...
(Date:5/23/2017)... ... May 22, 2017 , ... ... in San Diego, California, this August will feature high-level speakers on quantum ... vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical sciences meeting in ...
(Date:5/23/2017)... Philadelphia, PA. (PRWEB) , ... May 23, 2017 ... ... Clinical Works as Vice President of Clinical Operations. She brings years ... Pharmaceuticals, and Yaupon Therapeutics. From her professional foundation as a licensed occupational therapist, ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):